Frederik Kraglund

Frederik Kraglund

Auto-generated profile, based on publicly available information

Frederik Kraglund

Department of Hepatology and Gastroenterology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
PJPeter Jepsen
Peter Jepsen
FKFrederik Kraglund
Frederik Kraglund
JWJoe West
Joe West
GVGerda E. Villadsen
Gerda E. Villadsen
HSHenrik Toft Sørensen
Henrik Toft Sørensen
HVHendrik Vilstrup
Hendrik Vilstrup

1 January 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
FKFrederik Kraglund
Frederik Kraglund
TDThomas Deleuran
Thomas Deleuran
GAGro Askgaard
Gro Askgaard
KFKate M Fleming
Kate M Fleming
PJPeter Jepsen
Peter Jepsen
Purpose: Alcohol consumption has decreased in Denmark in recent years. We aimed to illustrate and investigate the developments in the incidence, hospital care, and mortality of alcohol-related liver disease (ALD) in Denmark during the last 25 years. Patients and Methods: Through nationwide healthcare registries, we identified all Danish patients with incident ALD in 1994– 2018. We computed standardized incidence rates by sex, age, and geography, age-specific incidence rates by birth cohort, and standardized prevalence. We enumerated inpatient admissions, days of admission, outpatient visits, and emergency room visits. Lastly, we estimated relative risks of mortality, standardized mortality rates, and the proportion of deaths caused by ALD. Results: The standardized incidence rate decreased from its peak at 357 per 1,000,000 in 2009 to 240 per 1,000,000 in 2018, and the decrease was evident for both sexes and all age groups below 70 years. The standardized prevalence was stable around 0.22% from 2011 onwards. There was an almost fivefold geographic variation in standardized incidence by municipalities, and age-specific incidence rates decreased sequentially with each 5-year birth cohort after 1960. The number of inpatient admissions, days of admission, and emergency room visits decreased during the study period, while the number of outpatient visits was stable. For patients diagnosed in 2014– 2018 compared to 1994– 1998, the relative risk of 1-year mortality was 0.83 (95% confidence interval: 0.78– 0.87), and the standardized mortality along with the proportion of deaths caused by ALD decreased during the study period. Conclusion: The incidence of ALD decreased from 357 to 240 per 1,000,000 over the last 10 years in Denmark. During the same period, the prevalence remained stable around 0.22% and mortality decreased. Additionally, the burden of ALD on hospital care decreased significantly between 1994 and 2018. We anticipate a further decrease in the incidence of ALD in the future.

1 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
GAGro Askgaard
Gro Askgaard
PJPeter Jepsen
Peter Jepsen
MJMorten Daniel Jensen
Morten Daniel Jensen
AKAnna Emilie Kann
Anna Emilie Kann
JMJoanne Morling
Joanne Morling
JWJoe West
Joe West
INTRODUCTION: England has seen an increase in deaths due to alcohol-related liver disease (ALD) since 2001. We studied the influence of socioeconomic position on the incidence of ALD and the mortality after ALD diagnosis in England in 2001–2018. METHODS: This was an observational cohort study based on health records contained within the UK Clinical Practice Research Datalink covering primary care, secondary care, cause of death registration, and deprivation of neighborhood areas in 18.8 million residents. We estimated incidence rate and incidence rate ratios of ALD and hazard ratios of mortality. RESULTS: ALD was diagnosed in 57,784 individuals with a median age of 54 years and of whom 43% had cirrhosis. The ALD incidence rate increased by 65% between 2001 and 2018 in England to reach 56.1 per 100,000 person-years in 2018. The ALD incidence was 3-fold higher in those from the most deprived quintile vs those from the least deprived quintile (incidence rate ratio 3.30, 95% confidence interval 3.21–3.38), with reducing inequality at older than at younger ages. For 55- to 74-year-olds, there was a notable increase in the incidence rate between 2001 and 2018, from 96.1 to 158 per 100,000 person-years in the most deprived quintile and from 32.5 to 70.0 in the least deprived quintile. After ALD diagnosis, the mortality risk was higher for patients from the most deprived quintile vs those from the least deprived quintile (hazard ratio 1.22, 95% confidence interval 1.18–1.27), and this ratio did not change during 2001–2018. DISCUSSION: The increasing ALD incidence in England is a greater burden on individuals of low economic position compared with that on those of high socioeconomic position. This finding highlights ALD as a contributor to inequality in health.

1 January 2023 in Hepatology Communications
Verified
Journal Article
Open access
FKFrederik Kraglund
Frederik Kraglund
DCDiana H. Christensen
Diana H. Christensen
AEAndreas H. Eiset
Andreas H. Eiset
GVGerda E. Villadsen
Gerda E. Villadsen
JWJoe West
Joe West
PJPeter Jepsen
Peter Jepsen
Background and Aims: Observational studies have shown an association between statin or aspirin use and a decreased risk of HCC, but the effects of a well-defined treatment strategy remain unknown. We emulated trials of the effects of continuous statin or aspirin use on HCC risk in patients with cirrhosis due to alcohol-related liver disease (ALD cirrhosis). Approach and Results: We specified target trials for statins and, separately, aspirin and emulated them using Danish health care registries. All eligible patients with ALD cirrhosis diagnosed in 2000–2018 were included in either an exposed or an unexposed arm. Patients were followed until HCC or death without HCC. The 5-year risk of HCC was estimated using marginal structural models with inverse probability weighting. Using statins continuously for 5 years compared with not using statins resulted in a relative risk (RR) of HCC of 0.67 (95% CI: 0.45–0.91). The RR of death without HCC was 0.69 (95% CI: 0.65–0.77). For aspirin, the RR was 1.05 (95% CI: 0.60–1.42) for HCC and 1.02 (95% CI: 0.95–1.09) for death without HCC. Conclusions: In patients with ALD cirrhosis, 5 years of continuous statin use resulted in a 33% RR reduction of HCC (number needed to treat = 94) and a 31% RR reduction of death without HCC (number needed to treat = 7). Such strong causal effects are implausible and best explained by uncontrollable confounding, highlighting the need for randomized trials. Aspirin use likely does not affect the risk of HCC or death without HCC.

1 September 2021 in Journal of Hepatology
Verified
Journal Article
Closed access
FKFrederik Kraglund
Frederik Kraglund
RGRasmus Hvidbjerg Gantzel
Rasmus Hvidbjerg Gantzel
PJPeter Jepsen
Peter Jepsen
NANiels Kristian Aagaard
Niels Kristian Aagaard

16 June 2019 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
FKFrederik Kraglund
Frederik Kraglund
PJPeter Jepsen
Peter Jepsen
NANerijus Amanavicius
Nerijus Amanavicius
NANiels Kristian Aagaard
Niels Kristian Aagaard
Background and aims: Accurate estimates of the long-term risks of adverse outcomes after transjugular intrahepatic portosystemic shunt (TIPS) treatment are needed. The aim of this cohort study was to estimate the risks of stent dysfunction, variceal bleeding, refractory ascites, hepatic encephalopathy (HE), and death after TIPS treatment. Methods: We extracted data from electronic medical records of 104 consecutive TIPS patients. Gore® Viatorr® TIPS endoprostheses were used in all patients. We conducted competing risks analysis of the risk of stent dysfunction and variceal bleeding, and Kaplan–Meier estimation of overall survival. Results: The overall 1-year survival after TIPS insertion was 82% (95% confidence interval [CI]: 73–88%), and the 1-year risk of stent dysfunction was 15% (95% CI: 9–22%). In patients who had a TIPS for variceal bleeding, the 1-year risk of rebleeding was 23% (95% CI: 13–35%). In patients who had a TIPS for refractory ascites, the risk of having an unsuccessful ascites outcome 1 year after TIPS for refractory ascites was 35% (95% CI: 21–52%). Overall, the 1-year risk of overt HE was 38% (95% CI: 32–43%). The risk of experiencing any of the defined complications during the first year was 56% (95% CI: 45–66%). Conclusion: TIPS is an effective treatment for variceal bleeding and refractory ascites in most cases, but more than half of the patients experience either death, stent dysfunction, recurrence of symptoms, or overt HE within the first year after the procedure.